AtriCure, Inc. (ATRC)

NASDAQ: ATRC · IEX Real-Time Price · USD
41.77
-1.31 (-3.04%)
May 18, 2022 4:00 PM EDT - Market closed
Market Cap1.93B
Revenue (ttm)289.63M
Net Income (ttm)51.93M
Shares Out46.29M
EPS (ttm)1.09
PE Ratio38.32
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume305,373
Open42.08
Previous Close43.08
Day's Range40.74 - 42.75
52-Week Range38.64 - 89.18
Beta1.10
AnalystsBuy
Price Target82.28 (+97.0%)
Earnings DateMay 3, 2022

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and ...

IndustryHealth Care Equipment & Supplies
IPO DateAug 5, 2005
Employees875
Stock ExchangeNASDAQ
Ticker SymbolATRC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ATRC stock is "Buy." The 12-month stock price forecast is 82.28, which is an increase of 96.98% from the latest price.

Price Target
$82.28
(96.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

AtriCure Reports First Quarter 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-oper...

2 weeks ago - Business Wire

AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-oper...

1 month ago - Business Wire

AtriCure to Announce First Quarter 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-ope...

1 month ago - Business Wire

Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positiv...

3 months ago - Zacks Investment Research

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results

MASON, Ohio,--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-ope...

3 months ago - Business Wire

AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

AtriCure Publishes Inaugural ESG Report

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-oper...

3 months ago - Business Wire

AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

3 months ago - Business Wire

AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-ope...

3 months ago - Business Wire

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-ope...

4 months ago - Business Wire

AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

4 months ago - Business Wire

AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

6 months ago - Business Wire

AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

AtriCure Reports Third Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 20...

6 months ago - Business Wire

Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

AtriCure to Participate in Upcoming Investor Conferences

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

6 months ago - Business Wire

AtriCure to Announce Third Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...

7 months ago - Business Wire

AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

8 months ago - Business Wire

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

AtriCure Reports Second Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2...

9 months ago - Business Wire

AtriCure to Participate at the Canaccord 41st Annual Growth Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

9 months ago - Business Wire

AtriCure to Announce Second Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...

10 months ago - Business Wire

AtriCure Names Two New Members to the Board of Directors

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. ...

11 months ago - Business Wire